肿瘤细胞治疗研究
ALL SOURCES
TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with
这些发现凸显了TLS作为NSCLC-BM患者预后生物标志物和潜在治疗靶点的重要性。
Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibit
脑转移是晚期非小细胞肺癌（NSCLC）的常见并发症，导致预后不良并降低免疫检查点抑制剂（ICIs）的疗效。
Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution.
rrTNBC代表一种独特的、高度侵袭性的表型，倾向于内脏和脑转移，对常规铂类挽救治疗反应不佳。这些发现与rrTNBC内侵袭性克隆演化一致，并凸显出迫切需要在这一点高风险人群中前瞻性评估新型治疗策略。
Decoding the mechanisms underlying breast cancer brain metastasis: paving the way for precision therapeutics.
脑转移的发生是乳腺癌患者生存率显著降低的主要原因。
Manganese-based virus-mimicking nanomedicine with triple immunomodulatory functions inhibits breast cancer brain metastasis.
本研究表明，具有三重免疫调节作用的Vir-HD@HM为脑转移患者提供了一种令人鼓舞的治疗选择。
CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report an
免疫检查点抑制剂（ICIs）显著改善了晚期肺癌患者的生存。
Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis.
脑转移（BM）的发病率正逐渐升高，其预后和治疗效果均较差。
Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
BCBM中TMB和TIL相对较低。在BCBM与配对的PT/ECM之间，可操作GA具有可比的一致性。因此，当有BCBM标本可用时，对BCBM进行基因组检测以识别潜在的新治疗靶点是合理的，因为约31%的样本携带额外的可操作GA。
Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
脑转移标志着多种晚期癌症进展中的不利节点，主要原发于肺癌、乳腺癌和黑色素瘤，中位生存时间接近 6 个月。
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy.
HER2 阳性乳腺癌脑转移（HER2 + BCBM）是一种复发率高、预后差的难治性恶性肿瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。
